Another Look at the Economics of the UK CMA’s Phenytoin Case

John Davies () and Jorge Padilla ()
Additional contact information
John Davies: Compass Lexecon
Jorge Padilla: Compass Lexecon

A chapter in Excessive Pricing and Competition Law Enforcement, 2018, pp 71-97 from Springer

Abstract: Abstract Davies and Padilla examine the UK Competition and Markets Authority’s 2016 decision to penalise Pfizer and Flynn Pharma for excessive pricing of phenytoin, an off-patent anti-epilepsy drug. The authors describe the CMA’s assessment of the gap between prices and cost and note that this same evidence is used in assessment of each of market definition, dominance and abuse. The CMA properly considered other evidence too, but this could serve as a precedent for a fragile and unreliable approach to assessing excessive pricing. The CMA found the price excessive ‘in itself’, rather than placing weight on comparator prices: a more appropriate measure of value. The authority imposed a fine uplifted by 400% for ‘deterrence’, and the authors question how realistic such deterrence objectives are, for excessive pricing provisions.

Date: 2018
References: Add references at CitEc
Citations:

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:intchp:978-3-319-92831-9_3

Ordering information: This item can be ordered from
http://www.springer.com/9783319928319

DOI: 10.1007/978-3-319-92831-9_3

Access Statistics for this chapter

More chapters in International Law and Economics from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().